NCT03211741View on ClinicalTrials.gov

Longterm Efficiency and Safety of Intravitreal Injections With Bevacizumab in Patients With Neovascularisation or Macular Edema

PHASE4RecruitingINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

November 22, 2013

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Retinal NeovascularizationMacular Edema
Interventions
DRUG

Bevacizumab Injection [Avastin]

Bevacizumab 1.25mg/0.05 mL will be injected intravitreally using one 30-gauge x 1/2-inch injection needle vials are for single eye use only.

Trial Locations (1)

9000

RECRUITING

Ghent University Hospital, Ghent

All Listed Sponsors
lead

University Hospital, Ghent

OTHER